Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia.
In a double-blind study, 12 consecutive patients with acute promyelocytic leukaemia were randomised either to tranexamic acid (TA group) or to placebo (control group) for 6 days to see whether inhibition of fibrinolysis would reduce haemorrhage and transfusion requirements. The total study period was 14 days. In the TA group, there were fewer haemorrhagic episodes, as determined by a scoring system. Packed red cell transfusion requirements decreased; and fewer additional platelet concentrate transfusions were needed. These beneficial effects were more pronounced in the second week. There were no thromboembolic complications.
Avvisati
G
G
Department of Human Biopathology, University La Sapienza, Rome, Italy.
ten Cate
J W
JW
Büller
H R
HR
Mandelli
F
F
D000293:Adolescent; D000328:Adult; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D017707:Erythrocyte Transfusion; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000097:blood; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000150:complications*; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D011897:Random Allocation; D012720:Severity of Illness Index; D013997:Time Factors; D014148:Tranexamic Acid / Q000627:therapeutic use*
D003509:Cyclohexanecarboxylic Acids; D005338:Fibrin Fibrinogen Degradation Products; D014148:Tranexamic Acid